Brief: Adial Pharma Provides Updates After FDA’s Favorable EOP2 Feedback on AD04 for Alcohol Use Disorder Treatment
16/09/2025 13:33
Sept 16 (Reuters) - Adial Pharmaceuticals Inc ADIL.O: ADIAL PHARMACEUTICALS PROVIDES BUSINESS UPDATE FOLLOWING FAVORABLE COMMENTS FROM FDA END-OF-PHASE 2 (EOP2) MEETING FOR AD04 Source text: ID:nGNX1P5Kym Further company coverage: ADIL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adial Pharmaceuticals
See all newsBrief: Adial Pharmaceuticals Announces Name Change To Azora Therapeutics
Brief: Adial Pharmaceuticals Announces Planned Appointment Of Celia Economides As Chief Financial Officer
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Adial Pharmaceuticals - Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)